About Sutro Biopharma

At Sutro Biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer therapeutics and autoimmune disease — Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Learn More


Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency.

Learn More


Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

Learn More

Recent News


Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018– Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug.. Read More →

Sutro Biopharma Announces $85.0 Million Initial Public Offering

South San Francisco, California – September 26, 2018.  Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging.. Read More →


At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.

Learn More